Prevalence and prognostic role of triple-negative breast cancer by race: A surveillance study

Clinical Breast Cancer

Volumn 11, Issue 5, 2011, Pages 332-341

  Swede, Helen ^a   Gregorio, David I ^a   Tannenbaum, Susan H ^b   Brockmeyer, Jessica A ^a   Ambrosone, Christine ^c   Wilson, Lori L ^b   Pensa, Mellisa A ^a   Gonsalves, Lou ^d   Stevens, Richard G ^a   Runowicz, Carolyn D ^b  

^a UNIVERSITY OF CONNECTICUT SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CONNECTICUT HEALTH CENTER   (United States)

^c ROSWELL PARK CANCER INSTITUTE   (United States)

^d Department of Public Health ^*  (United States)

Author keywords

Biologic markers; Breast neoplasms; Health status disparities; HER2; Race ethnicity; Triple negative breast cancer

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR;

ADULT; ARTICLE; CANCER MORTALITY; CANCER PROGNOSIS; CANCER REGISTRY; CANCER SIZE; CANCER SURVIVAL; CAUCASIAN; FEMALE; FOLLOW UP; HUMAN; MAJOR CLINICAL STUDY; NEGRO; PHENOTYPE; RACE; RACE DIFFERENCE; SURVIVAL TIME; TRIPLE NEGATIVE BREAST CANCER; BREAST TUMOR; CANCER STAGING; ETHNIC GROUP; ETHNOLOGY; LUNG CARCINOMA; MEDULLARY CARCINOMA; METABOLISM; MIDDLE AGED; PAGET NIPPLE DISEASE; PATHOLOGY; PREVALENCE; PROGNOSIS; STATISTICS; SURVIVAL; UNITED STATES;

BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, LOBULAR; CARCINOMA, MEDULLARY; ETHNIC GROUPS; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM STAGING; PREVALENCE; PROGNOSIS; RECEPTOR, ERBB-2; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; SEER PROGRAM; SURVIVAL ANALYSIS; UNITED STATES;

EID: 84855720353     PISSN: 15268209     EISSN: 19380666     Source Type: Journal    
DOI: 10.1016/j.clbc.2011.04.004     Document Type: Article

References (47)

1. Elledge RM, Clark GM, Chamness GC, et al. Tumor biologic factors and breast cancer prognosis among white, hispanic, and black women in the United States. J Natl Cancer Inst 1994; 86: 705-12. (Pubitemid 24138977)
2. Newman LA, Griffith KA, Jatoi I, et al. Meta-analysis of survival in African American and white American patients with breast cancer: ethnicity compared with socioeconomic status. J Clin Oncol 2006; 24: 1342-9. (Pubitemid 46621996)
3. Blackman DJ, Masi CM. Racial and ethnic disparities in breast cancer mortality: are we doing enough to address the root causes? J Clin Oncol 2006; 24: 2170-8. (Pubitemid 46655602)
4. Surveillance Epidemiology and End Results: Cancer statistics review, 1975-2006. Available at http://seer.cancer.gov/csr/1975-2006/. Accessed May 8, 2011.
5. Clegg LX, Reichman ME, Miller BA, et al. Impact of socioeconomic status on cancer incidence and stage at diagnosis: selected findings from the surveillance, epidemiology, and end results: national longitudinal mortality study. Cancer Causes Control 2009; 20: 417-35.
6. Li CI, Malone KE, Daling JR. Differences in breast cancer stage, treatment, and survival by race and ethnicity. Arch Intern Med 2003; 163: 49-56. (Pubitemid 36091600)
7. Jones BA, Kasl SV, Howe CL, et al. African-American/white differences in breast carcinoma: P53 alterations and other tumor characteristics. Cancer 2004; 101: 1293-301. (Pubitemid 39180384)
8. Perou CM, Sorlie T, Eisen MB, et al. Molecular portraits of human breast tumours. Nature 2000; 406: 747-52.
9. Sorlie T. Molecular portraits of breast cancer: Tumour subtypes as distinct disease entities. Eur J Cancer 2004; 40: 2667-75. (Pubitemid 39574720)
10. Rakha EA, Ellis IO. Triple-negative/basal-like breast cancer: review. Pathology 2009; 41: 40-7.
11. Sotiriou C, Pusztai L. Gene-expression signatures in breast cancer. N Engl J Med 2009; 360: 790-800.
12. Carey LA, Perou CM, Livasy CA, et al. Race, breast cancer subtypes, and survival in the Carolina Breast Cancer Study. JAMA 2006; 295: 2492-502. (Pubitemid 43854964)
13. Schneider BP, Winer EP, Foulkes WD, et al. Triple-negative breast cancer: risk factors to potential targets. Clin Cancer Res 2008; 14: 8010-8.
14. Cheang MC, Chia SK, Voduc D, et al. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst 2009; 101: 736-50.
15. Greene FL, Page DL, Fleming ID, et al. AJCC Cancer Staging Handbook. 6th ed. Chicago, IL: American Joint Committee on Cancer; 2002: 469.
16. Lund MJ, Trivers KF, Porter PL, et al. Race and triple negative threats to breast cancer survival: a population-based study in Atlanta, GA. Breast Cancer Res Treat 2009; 113 : 357-70.
17. Stead LA, Lash TL, Sobieraj JE, et al. Triple-negative breast cancers are increased in black women regardless of age or body mass index. Breast Cancer Res 2009; 11: R18.
18. Onitilo AA, Engel JM, Greenlee RT, et al. Breast cancer subtypes based on ER/PR and Her2 expression: comparison of clinicopathologic features and survival. Clin Med Res 2009; 7: 4-13.
19. Fritz A, Jack A, Parkin DM, et al. International Classification of Diseases for Oncology. 3rd ed. Geneva, Switzerland: World Health Organization; 2000.
20. Gusterson BA, Gelber RD, Goldhirsch A, et al. Prognostic importance of c-erbB-2 expression in breast cancer. International (Ludwig) Breast Cancer Study Group. J Clin Oncol 1992; 10: 1049-56.
21. Donegan WL. Tumor-related prognostic factors for breast cancer. CA Cancer J Clin 1997; 47: 28-51. (Pubitemid 27050848)
22. Polednak AP. Comorbid diabetes mellitus and risk of death after diagnosis of colorectal cancer: a population-based study. Cancer Detect Prev 2006; 30: 466-72. (Pubitemid 44750406)
23. Wolff AC, Hammond ME, Schwartz JN, et al. American Society of Clinical Oncology/ College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol 2007; 25: 118-45. (Pubitemid 350003059)
24. Zarbo RJ, Hammond ME. Conference summary, strategic science symposium. her-2/neu testing of breast cancer patients in clinical practice. Arch Pathol Lab Med 2003; 127: 549-53. (Pubitemid 36534937)
25. Persons DL, Tubbs RR, Cooley LD, et al. HER-2 fluorescence in situ hybridization: results from the survey program of the College of American Pathologists. Arch Pathol Lab Med 2006; 130(3): 325-31.
26. Pensa M, Swede H, Brockmeyer JA, et al. Patterns of HER2 testing in the management of primary breast cancer. Cancer Epidemiol 2009; 33: 113-7.
27. Trivers KF, Lund MJ, Porter PL, et al. The epidemiology of triple-negative breast cancer, including race. Cancer Causes Control 2009; 20: 1071-82.
28. Swede H, Moysich KB, Winston JS, et al. Variation of the prognostic significance of HER-2 expression in breast cancer according to tumor size. Breast J 2003; 9: 98-105. (Pubitemid 37051577)
29. Kwan ML, Kushi LH, Weltzien E, et al. Epidemiology of breast cancer subtypes in two prospective cohort studies of breast cancer survivors. Breast Cancer Res 2009; 11(3): R31.
30. Lund MJ, Butler EN, Hair BY, et al. Age/race differences in HER2 testing and in incidence rates for breast cancer triple subtypes: A population-based study and first report. Cancer 2010 Mar 24.
31. Morris GJ, Naidu S, Topham AK, et al. Differences in breast carcinoma characteristics in newly diagnosed African-American and Caucasian patients: a single-institution compilation compared with the National Cancer Institute's Surveillance, Epidemiology, and End Results database. Cancer 2007; 110 876-84. (Pubitemid 47257667)
32. Kovi J, Mohla S, Norris HJ, et al. Breast lesions in black women. Pathol Annu 1989; 24(Pt 1): 199-218.
33. Al-Abbadi MA, Washington TA, Saleh HA, et al. Differential expression of HER-2/ NEU receptor of invasive mammary carcinoma between Caucasian and African American patients in the Detroit metropolitan area. Correlation with overall survival and other prognostic factors. Breast Cancer Res Treat 2006; 97: 3-8.
34. Stark AT, Claud S, Kapke A, et al. Race modifies the association between breast carcinoma pathologic prognostic indicators and the positive status for HER-2/neu. Cancer 2005; 104: 2189-96. (Pubitemid 41579966)
35. Anderson WF, Chu KC, Chang S, et al. Comparison of age-specific incidence rate patterns for different histopathologic types of breast carcinoma. Cancer Epidemiol Biomarkers Prev 2004; 13: 1128-35. (Pubitemid 38917901)
36. Walker RA, Martin CV. The aged breast. J Pathol 2007; 211: 232-40. (Pubitemid 46195521)
37. Middleton LP, Chen V, Perkins GH, et al. Histopathology of breast cancer among African-American women. Cancer 2003; 97(1 suppl): 253-7. (Pubitemid 36033847)
38. Marginean F, Rakha EA, Ho BC, et al. Histological features of medullary carcinoma and prognosis in triple-negative basal-like carcinomas of the breast. Mod Pathol 2010; 23: 1357-63.
39. Huo D, Ikpatt F, Khramtsov A, et al. Population differences in breast cancer: survey in indigenous African women reveals over-representation of triple-negative breast cancer. J Clin Oncol 2009; 27: 4515-21.
40. Troester MA, Swift-Scanlan T. Challenges in studying the etiology of breast cancer subtypes. Breast Cancer Res 2009; 11: 104.
41. Lund MJ, Brawley OP, Ward KC, et al. Parity and disparity in first course treatment of invasive breast cancer. Breast Cancer Res Treat 2008; 109: 545-57. (Pubitemid 351692062)
42. Reichman ME, Altekruse S, Li CI, et al. Feasibility study for collection of HER2 data by National Cancer Institute (NCI) Surveillance, Epidemiology, and End Results (SEER) Program central cancer registries. Cancer Epidemiol Biomarkers Prev 2010; 19(1): 144-7.
43. Wu Y, Khan H, Chillar R, et al. Prognostic value of plasma HER-2/neu in African American and Hispanic women with breast cancer. Int J Oncol 1999; 14: 1021-37.
44. Pritchard KI, Shepherd LE, O'Malley FP, et al. HER2 and responsiveness of breast cancer to adjuvant chemotherapy. N Engl J Med 2006; 18: 354: 2103-11. (Pubitemid 43736610)
45. Owens MA, Horten BC, Da Silva MM. HER2 amplification ratios by fluorescence in situ hybridization and correlation with immunohistochemistry in a cohort of 6556 breast cancer tissues. Clin Breast Cancer 2004; 5: 63-9. (Pubitemid 38821193)
46. Anderson WF, Luo S, Chatterjee N, et al. Human epidermal growth factor receptor-2 and estrogen receptor expression, a demonstration project using the residual tissue repository of the Surveillance, Epidemiology, and End Results (SEER) program. Breast Cancer Res Treat 2009; 113: 189-96.
47. Glaser SL, Clarke CA, Gomez SL, et al. Cancer surveillance research: a vital subdiscipline of cancer epidemiology. Cancer Causes Control 2005; 16: 1009-19. (Pubitemid 41355998)